PERSONALIZED MEDICINE BIOMARKERS MARKET Challenges and Opportunities

One of the major challenges faced by the global personalized medicine biomarkers market is the high costs with the development of personalized medicines. Developing biomarkers and companion diagnostics require huge investments in R&D. Clinical validation of biomarkers is a lengthy and expensive process requiring large clinical trials. Manufacturing of precision therapies involves high capital investments due to stringent regulatory standards. Additionally, the testing and analysis of biomarkers is technically complex and cost intensive which increases the overall cost of personalized therapies.

Market Opportunity - Growing demand for targeted therapies in oncology

The oncology segment presents a significant opportunity for the personalized medicine biomarkers market, driven by rising cancer cases and the need for targeted therapies. Biomarkers enable the identification of gene mutations, allowing for tailored drug treatments that improve outcomes and minimize side effects. Growing investments and advancements in genomic and proteomic technologies are further expanding biomarker discovery, enhancing personalized cancer care options. For instance, in October 2024, SandboxAQ partnered with Sanofi, pharmaceutical companies, to utilize large quantitative models for biomarker discovery, aiming to enhance trust in clinical development.